Dorzolomide HCI OK for use in children

The FDA has approved Merck Human Health's dorzolomide HCI (Trusopt) ophthalmic solution 2% for use in pediatric patients. The drug is used to treat elevated IOP in patients with ocular hypertension or open-angle glaucoma.

Related Videos
View All
Related Content

Eyenuk gets greenlight to market AI screening system in European Union

January 31st 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Study: Retina specialists gain awareness of biosimilars

January 31st 2023

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

May 12th 2022

HuidaGene Therapeutics gains FDA clearance for multinational clinical trial of investigational new drug

January 30th 2023

Foundation Fighting Blindness to kick off PRPH2 and Associated Retinal Diseases Workshop

January 30th 2023

Eyenuk gets greenlight to market AI screening system in European Union

January 31st 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Study: Retina specialists gain awareness of biosimilars

January 31st 2023

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

May 12th 2022

HuidaGene Therapeutics gains FDA clearance for multinational clinical trial of investigational new drug

January 30th 2023

Foundation Fighting Blindness to kick off PRPH2 and Associated Retinal Diseases Workshop

January 30th 2023

Eyenuk gets greenlight to market AI screening system in European Union

January 31st 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Study: Retina specialists gain awareness of biosimilars

January 31st 2023

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

May 12th 2022

HuidaGene Therapeutics gains FDA clearance for multinational clinical trial of investigational new drug

January 30th 2023

Foundation Fighting Blindness to kick off PRPH2 and Associated Retinal Diseases Workshop

January 30th 2023
Advertise
Privacy
Editorial
Terms and Conditions
Contact Us
Do Not Sell My Personal Information
Job Board
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.